185 related articles for article (PubMed ID: 35739379)
1. Protein Tyrosine Phosphatase SHP2 Controls Interleukin-8 Expression in Breast Cancer Cells.
Amante RJ; Auf der Maur P; Richina V; Sethi A; Iesmantavicius V; Bonenfant D; Aceto N; Bentires-Alj M
J Mammary Gland Biol Neoplasia; 2022 Jun; 27(2):145-153. PubMed ID: 35739379
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
[TBL] [Abstract][Full Text] [Related]
3. PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer.
Amante RJ; Jehanno C; De Silva D; Coissieux MM; Ackerknecht M; Romanet V; Sethi A; Hamelin B; Preca BT; Piscuoglio S; Ng CKY; Mohseni M; Bentires-Alj M
J Mammary Gland Biol Neoplasia; 2023 Jun; 28(1):13. PubMed ID: 37294349
[TBL] [Abstract][Full Text] [Related]
4. Src homology-2 domain-containing protein tyrosine phosphatase (SHP) 2 and p38 regulate the expression of chemokine CXCL8 in human astrocytes.
Mamik MK; Ghorpade A
PLoS One; 2012; 7(9):e45596. PubMed ID: 23029125
[TBL] [Abstract][Full Text] [Related]
5. Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells.
Sun X; Zhang J; Wang Z; Ji W; Tian R; Zhang F; Niu R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208810
[TBL] [Abstract][Full Text] [Related]
6. Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis.
Wang HC; Chiang WF; Huang HH; Shen YY; Chiang HC
BMC Cancer; 2014 Jun; 14():442. PubMed ID: 24931737
[TBL] [Abstract][Full Text] [Related]
7. The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling.
Fiebelkow J; Guendel A; Guendel B; Mehwald N; Jetka T; Komorowski M; Waldherr S; Schaper F; Dittrich A
Cell Commun Signal; 2021 Sep; 19(1):94. PubMed ID: 34530865
[TBL] [Abstract][Full Text] [Related]
8. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
[TBL] [Abstract][Full Text] [Related]
9. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
10. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
11. SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer.
Chen H; Libring S; Ruddraraju KV; Miao J; Solorio L; Zhang ZY; Wendt MK
Oncogene; 2020 Dec; 39(49):7166-7180. PubMed ID: 33033382
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor.
Li J; Kang Y; Wei L; Liu W; Tian Y; Chen B; Lin X; Li Y; Feng GS; Lu Z
PLoS One; 2014; 9(7):e102847. PubMed ID: 25048202
[TBL] [Abstract][Full Text] [Related]
13. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
[TBL] [Abstract][Full Text] [Related]
14. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells.
Fernandis AZ; Prasad A; Band H; Klösel R; Ganju RK
Oncogene; 2004 Jan; 23(1):157-67. PubMed ID: 14712221
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
Badache A; Hynes NE
Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
[TBL] [Abstract][Full Text] [Related]
16. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
[TBL] [Abstract][Full Text] [Related]
17. SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability
Yuan Y; Fan Y; Gao Z; Sun X; Zhang H; Wang Z; Cui Y; Song W; Wang Z; Zhang F; Niu R
Cancer Biol Med; 2020 Aug; 17(3):707-725. PubMed ID: 32944401
[No Abstract] [Full Text] [Related]
18. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S
Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822
[TBL] [Abstract][Full Text] [Related]
19.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
20. [SHP2 and MKP5 in P2Y purinergic receptor-mediated prostate cancer invasion].
He HY; Zheng J; Li Y; Heng WJ; Fang WG
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):288-92. PubMed ID: 16181551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
